Lion Biotechnologies (NASDAQ:IOVA) Receives Daily News Sentiment Rating of 0.12
News headlines about Lion Biotechnologies (NASDAQ:IOVA) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lion Biotechnologies earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1334490890434 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Lion Biotechnologies, Inc. (IOVA) Now Covered by Oppenheimer Holdings, Inc. (americanbankingnews.com)
- Lion Biotechnologies, Inc. (IOVA) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Lion Biotechnologies, Inc. (NASDAQ:IOVA) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
- Lion Biotechnologies reports 2Q loss (finance.yahoo.com)
A number of research firms recently weighed in on IOVA. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Lion Biotechnologies in a research note on Wednesday, June 7th. Zacks Investment Research raised shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Tuesday, July 18th. FBR & Co reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, May 18th. Jefferies Group LLC reissued a “buy” rating and issued a $11.00 target price on shares of Lion Biotechnologies in a research note on Thursday, May 18th. Finally, Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, May 17th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $13.88.
Lion Biotechnologies (NASDAQ:IOVA) opened at 5.60 on Tuesday. The firm has a 50-day moving average of $6.24 and a 200-day moving average of $6.86. The firm’s market capitalization is $351.05 million. Lion Biotechnologies has a 52-week low of $4.90 and a 52-week high of $9.58.
ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/lion-biotechnologies-nasdaqiova-receives-daily-news-sentiment-rating-of-0-12.html.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.